The ALS Association of Greater San Diego announced on Dec. 22 the donation of $200,000 from Paul Negulescu, Ph.D., one of two recipients of the 2022 Shaw Prize in Life Science and Medicine.
Someone whose pure love of baseball was passed down through generations like a perfect relay, center to short to home. A person whose passion for the game is a thread throughout his or her life.
Scientists at UF Scripps Biomedical Research have developed a potential medicine for a leading cause of ALS and dementia that works by eliminating disease-causing segments of RNA. The compound restored the health of neurons in the lab and rescued mice with the disease.
Researchers publish positive safety results for prosetin, a MAP4K inhibitor developed through a two-decade-long collaboration between Columbia researchers and a nonprofit, Project ALS
The beloved singer Roberta Flack has announced through a spokesperson that she is battling ALS. The brain disease called amyotrophic lateral sclerosis, or popularly known as Lou Gehrig's disease, has made it "impossible to sing and not easy to speak," the spokesperson said in a press release on Monday.
Besides the regulatory discussion, there are questions about pricing and reimbursement. Amylyx expects Relyvrio to become commercially available in the U.S. within the next four to six weeks.
On September 29, 2022, the FDA made the decision to approve AMX0035, Amylyx Pharmaceuticals’ coformulation of sodium phenylbutyrate/taurursodiol, representing a monumental victory for the amyotrophic lateral sclerosis (ALS) community and standing as a testament to the continued perseverance to advance the treatment landscape.
New target discovered and delivered into the clinic in just four years using CONVERGETM, Verge’s all-in-human, AI-powered platform
VRG50635 is one of the first drugs entirely discovered and developed from a tech-enabled platform to enter clinical trials